Law360, New York (December 15, 2006, 12:00 AM ET) -- Biotech partners in a transatlantic licensing dispute are on their way to arbitration after California’s Spectrum Pharmaceuticals Inc. accused its German partner of cutting it out of a multimillion dollar sublicensing agreement.
At stake is control over satraplatin, a promising prostate-cancer drug co-developed by Spectrum and its partner, GPC Biotech AG, which allegedly cut Spectrum out of $59 million worth of sublicensing deals with another German firm, Pharmion GmbH.
According to Irvine, Calif.-based Spectrum, GPC Biotech’s deal with Pharmion violated their licensing agreement, effectively ending it....
License Agreement Turns Biotech Partners Into Rivals
To view the full article, take a free trial now.
